X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES CIPLA JUBILANT LIFE SCIENCES/
CIPLA
 
P/E (TTM) x 15.4 33.7 45.6% View Chart
P/BV x 4.5 2.9 154.5% View Chart
Dividend Yield % 0.4 0.6 69.4%  

Financials

 JUBILANT LIFE SCIENCES   CIPLA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
CIPLA
Mar-18
JUBILANT LIFE SCIENCES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs187663 28.2%   
Low Rs65479 13.6%   
Sales per share (Unadj.) Rs364.3189.0 192.7%  
Earnings per share (Unadj.) Rs6.817.6 38.9%  
Cash flow per share (Unadj.) Rs24.534.0 72.0%  
Dividends per share (Unadj.) Rs3.003.00 100.0%  
Dividend yield (eoy) %2.40.5 453.4%  
Book value per share (Unadj.) Rs164.9176.7 93.3%  
Shares outstanding (eoy) m159.28805.12 19.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.33.0 11.4%   
Avg P/E ratio x18.432.5 56.7%  
P/CF ratio (eoy) x5.116.8 30.6%  
Price / Book Value ratio x0.83.2 23.6%  
Dividend payout %43.817.1 257.0%   
Avg Mkt Cap Rs m20,061459,724 4.4%   
No. of employees `0006.223.6 26.2%   
Total wages/salary Rs m11,05226,901 41.1%   
Avg. sales/employee Rs Th9,383.06,446.1 145.6%   
Avg. wages/employee Rs Th1,786.91,139.4 156.8%   
Avg. net profit/employee Rs Th176.3600.0 29.4%   
INCOME DATA
Net Sales Rs m58,034152,193 38.1%  
Other income Rs m1913,577 5.3%   
Total revenues Rs m58,224155,769 37.4%   
Gross profit Rs m5,78628,264 20.5%  
Depreciation Rs m2,81213,228 21.3%   
Interest Rs m3,2371,142 283.4%   
Profit before tax Rs m-7217,470 -0.4%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m2,145-775 -276.7%   
Tax Rs m6962,501 27.8%   
Profit after tax Rs m1,09014,166 7.7%  
Gross profit margin %10.018.6 53.7%  
Effective tax rate %-965.914.3 -6,746.5%   
Net profit margin %1.99.3 20.2%  
BALANCE SHEET DATA
Current assets Rs m29,280108,141 27.1%   
Current liabilities Rs m38,91238,322 101.5%   
Net working cap to sales %-16.645.9 -36.2%  
Current ratio x0.82.8 26.7%  
Inventory Days Days8497 87.0%  
Debtors Days Days5174 68.1%  
Net fixed assets Rs m55,712109,411 50.9%   
Share capital Rs m1551,610 9.6%   
"Free" reserves Rs m20,968140,682 14.9%   
Net worth Rs m26,265142,292 18.5%   
Long term debt Rs m17,16936,621 46.9%   
Total assets Rs m88,606228,606 38.8%  
Interest coverage x1.016.3 6.0%   
Debt to equity ratio x0.70.3 254.0%  
Sales to assets ratio x0.70.7 98.4%   
Return on assets %4.96.7 72.9%  
Return on equity %4.210.0 41.7%  
Return on capital %11.610.0 116.2%  
Exports to sales %37.832.8 115.3%   
Imports to sales %16.50-   
Exports (fob) Rs m21,93349,883 44.0%   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,00451,691 42.6%   
Fx outflow Rs m11,74921,033 55.9%   
Net fx Rs m10,25530,658 33.5%   
CASH FLOW
From Operations Rs m8,02614,628 54.9%  
From Investments Rs m-1,744-8,540 20.4%  
From Financial Activity Rs m-4,447-3,855 115.4%  
Net Cashflow Rs m1,8342,431 75.5%  

Share Holding

Indian Promoters % 45.6 16.0 285.0%  
Foreign collaborators % 3.5 20.8 16.8%  
Indian inst/Mut Fund % 8.7 12.2 71.3%  
FIIs % 21.2 23.7 89.5%  
ADR/GDR % 0.0 1.1 -  
Free float % 21.1 26.2 80.5%  
Shareholders   23,815 161,166 14.8%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   GSK PHARMA  NATCO PHARMA  BIOCON LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY19); Net Profit Up 67.2% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 67.2% YoY). Sales on the other hand came in at Rs 23 bn (up 38.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Nov 14, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS